Drug Trial Radar · NCT03776968
A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics
Last checked: Nov 20, 2026Latest source record: Oct 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
Oct 24, 2017
Primary completion
Jan 15, 2018
Study completion Jul 3, 2018
Sponsor
- Lead sponsor
- Hinova Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase I study evaluating HC-1119 single-dose pharmacokinetics and effect of food on its pharmacokinetics in healthy Chinese adults. The study primary objective is to evaluate the HC-1119 pharmacokinetic characteristics and the effect of food on its pharmacokinetics in healthy Chinese males, subsequent to a single oral administration of HC-1119 with different doses in healthy Chinese males.
Conditions
- Metastatic Castration Resistant Prostate Cancer
Interventions
HC1119Drug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma concentration-time curve from time 0 to infinity (∞) (AUC0-∞)Time frame: From the first dose of the study drug to day 50
- Area under the plasma concentration-time curve from time 0 to time t of the last measurable concentration(AUC0-t)Time frame: From the first dose of the study drug to day 50
- Peak concentration (Cmax)Time frame: From the first dose of the study drug to day 50
- Peak time (Tmax)Time frame: From the first dose of the study drug to day 50
- Elimination half life (t1/2)Time frame: From the first dose of the study drug to day 50
- Apparent clearance (CL/F) (prototype)Time frame: From the first dose of the study drug to day 50
- Apparent volume of distribution (Vd/F) (prototype)Time frame: From the first dose of the study drug to day 50
- Mean residence time (MRT)Time frame: From the first dose of the study drug to day 50
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Changhai Hospital Ethics Committee
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.